A novel role for drebrin in regulating progranulin bioactivity in bladder cancer. by Xu, Shi-Qiong et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Urology Faculty Papers Department of Urology
5-10-2015
A novel role for drebrin in regulating progranulin
bioactivity in bladder cancer.
Shi-Qiong Xu
Endocrine Mechanisms and Hormone Action Program, Department of Urology, Kimmel Cancer Center, Thomas Jefferson
University, Shi-Qiong.Xu@jefferson.edu
Simone Buraschi
Cancer Cell Biology and Signaling Program, Department of Pathology, Anatomy and Cell Biology, Kimmel Cancer Center,
Thomas Jefferson University, Simone.Buraschi@jefferson.edu
Alaide Morcavallo
Department of Urology and Biology of Prostate Cancer Program, Thomas Jefferson University; Department of Health and
Endocrinology, University Magna Graecia of Catanzaro
Marco Genua
Department of Urology and Biology of Prostate Cancer Program, Thomas Jefferson University
Tomoaki Shirao
Department of Neurobiology and Behavior, Gunma University School of Medicine
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/urologyfp
Part of the Urology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Urology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Xu, Shi-Qiong; Buraschi, Simone; Morcavallo, Alaide; Genua, Marco; Shirao, Tomoaki; Peiper,
Stephen C; Gomella, Leonard G; Birbe, Ruth; Belfiore, Antonino; Iozzo, Renato V; and Morrione,
Andrea, "A novel role for drebrin in regulating progranulin bioactivity in bladder cancer." (2015).
Department of Urology Faculty Papers. Paper 27.
http://jdc.jefferson.edu/urologyfp/27
Authors
Shi-Qiong Xu, Simone Buraschi, Alaide Morcavallo, Marco Genua, Tomoaki Shirao, Stephen C Peiper,
Leonard G Gomella, Ruth Birbe, Antonino Belfiore, Renato V Iozzo, and Andrea Morrione
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/urologyfp/27
Oncotarget10825www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 13
A novel role for drebrin in regulating progranulin bioactivity in 
bladder cancer
Shi-Qiong Xu1,*, Simone Buraschi2,*, Alaide Morcavallo1,3, Marco Genua1, 
Tomoaki Shirao4, Stephen C. Peiper2, Leonard G. Gomella1, Ruth Birbe2, 
Antonino Belfiore3, Renato V. Iozzo2, Andrea Morrione1
1Department of Urology and Biology of Prostate Cancer Program, Thomas Jefferson University, Philadelphia, PA, USA
2 Department of Pathology, Anatomy and Cell Biology and Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, 
Thomas Jefferson University, Philadelphia, PA, USA
3Department of Health and Endocrinology, University Magna Graecia of Catanzaro, Catanzaro, Italy
4Department of Neurobiology and Behavior, Gunma University School of Medicine, Showamachi, Maebashi, Japan
*These authors have contributed equally to this work
Correspondence to:
Andrea Morrione, e-mail: Andrea.Morrione@jefferson.edu
Renato V. Iozzo, e-mail: renato.iozzo@jefferson.edu
Keywords: Progranulin, drebrin, bladder cancer, migration, invasion and anchorage-independent growth
Received: October 13, 2014    Accepted: February 23, 2015    Published: March 12, 2015
ABSTRACT
We recently established a critical role for the growth factor progranulin in 
bladder cancer insofar as progranulin promotes urothelial cancer cell motility 
and contributes, as an autocrine growth factor, to the transformed phenotype by 
modulating invasion and anchorage-independent growth. In addition, progranulin 
expression is upregulated in invasive bladder cancer tissues compared to normal 
controls. However, the molecular mechanisms of progranulin action in bladder cancer 
have not been fully elucidated. In this study, we searched for novel progranulin-
interacting proteins using pull-down assays with recombinant progranulin and 
proteomics. We discovered that drebrin, an F-actin binding protein, bound progranulin 
in urothelial cancer cells. We characterized drebrin function in urothelial cancer cell 
lines and showed that drebrin is critical for progranulin-dependent activation of the 
Akt and MAPK pathways and modulates motility, invasion and anchorage-independent 
growth. In addition, drebrin regulates tumor formation in vivo and its expression is 
upregulated in bladder cancer tissues compared to normal tissue controls. Our data 
are translationally relevant as indicate that drebrin exerts an essential functional 
role in the regulation of progranulin action and may constitute a novel target for 
therapeutic intervention in bladder tumors. In addition, drebrin may serve as novel 
biomarker for bladder cancer.
INTRODUCTION
Bladder cancer (BC) is one of the most common 
cancers in the United States with 56,390 estimated new 
cases and 11,170 estimated deaths in 2014 [1]. Bladder 
tumors show diverse histopathological patterns and 
clinical behaviors [2] making this a serious hindrance in 
the management of bladder tumors. The clinical stage of 
BC is dependent on the depth of tumor invasion [3] and, 
although the prognosis for low-grade tumors is generally 
good, 10%–15% of these patients will later develop 
invasive disease. For invasive tumors instead, prognosis 
is much less favorable, with only 50% survival at 5 years. 
Invasive tumors frequently progress to life-threatening 
metastases, which are associated with a 5 year survival 
rate of ~6% [2]. Thus, understanding the mechanisms that 
regulate bladder tumor invasion and progression toward 
metastasis is critical to predict and treat this devastating 
condition in bladder cancer patients.
The growth factor progranulin, also known as 
proepithelin, PCDGF, granulin-epithelin precursor or 
acrogranin, is a secreted glycoprotein which plays an 
Oncotarget10826www.impactjournals.com/oncotarget
important role in cell proliferation, wound healing and 
transformation in several cancer model systems [4–6]. 
In addition, progranulin regulates inflammation and 
neurodegeneration [7] and low levels of circulating 
progranulin are associated with fronto-temporal dementia 
(FTD). Progranulin interacts with the protein core of the 
heparan sulfate proteoglycan perlecan and it has been 
suggested that this interaction leads to a pro-angiogenic 
and proinvasive phenotype [8]. We have discovered 
that progranulin plays a critical role in bladder cancer 
by promoting urothelial cancer cell motility [9], and 
demonstrated that progranulin contributes as an autocrine 
growth factor to the transforming phenotype by regulating 
invasion and anchorage-independent growth [10, 11]. In 
addition, progranulin is overepressed in invasive bladder 
cancer tissues vis-à-vis non-neoplastic tissues and it is 
detectable in the urine [11]. Thus, progranulin may be critical 
for the transition to the invasive phenotype in bladder cancer 
and may serve as a novel biomarker for bladder cancer.
Despite the increasing interest in progranulin 
biology, progranulin’s mode of action is still poorly 
characterized. Furthermore, very few proteins that mediate 
the early stages of progranulin signaling from the plasma 
membrane have been so far characterized.
Previous studies have identified proteins of ~130 
kDa as putative progranulin receptors [12, 13] and 
more recently, sortilin has been identified as a novel 
progranulin-interacting protein using membrane binding 
with alkaline phosphatase-labeled progranulin. Sortilin is 
a single-pass Type I transmembrane protein of the Vps10 
family that is localized to the cell surface, secretory, 
and endocytic compartments of eukaryotic cells [14]. 
However, sortilin acts as negative regulator of progranulin 
levels and signaling by targeting progranulin for lysosomal 
degradation [14].
Progranulin has been shown to bind TNF receptors 
1 and 2 and decrease TNF-dependent activation of MAPK 
(ERKs, p38 and JNK) by disturbing the TNF/TNFR 
interaction [15]. These results therefore do not support a 
role of TNFRs as bona fide progranulin signaling interacting 
partner. In addition, more recent papers have challenged the 
physical and functional interaction between progranulin 
and TNFRs [16], suggesting that additional experiments are 
necessary to clarify these contradictory results. In addition, 
in the presence of CpG-ONDs progranulin proteolytic 
fragments are soluble cofactors for Toll-like receptor 9 
(TLR9) and contribute to innate immunity [17]. Furthermore, 
Tropomyosin 3 has been more recently reported as a novel 
progranulin-interacting protein in hepatocellular carcinoma 
cells [18], but the biological significance of this interaction 
has not been yet fully characterized.
In search for novel progranulin interacting proteins 
we performed pull-down assays with recombinant 
progranulin and protein extracts of 5637 bladder cancer 
cells. Proteomic analysis identified the F-actin-binding 
protein drebrin (developmentally regulated brain protein) 
[19, 20] as a novel progranulin-binding partner. We have 
characterized the biological significance of this interaction 
in invasive bladder cancer cells and showed that drebrin 
is critical for the regulation of progranulin-induced cell 
motility and invasion by mediating progranulin-induced 
F-acting remodeling. Furthermore, drebrin is essential 
for progranulin-induced activation of the Akt and MAPK 
signaling pathways. Significantly, drebrin depletion in 
tumorigenic urothelial cancer cells inhibits motility, 
anchorage-independent growth and tumor formation in 
vivo. In addition, drebrin is upregulated in high grade 
bladder cancer tissues compared to lower grade and 
normal tissue controls.
Collectively, we have identified drebrin as a novel 
progranulin-interacting protein and presented evidences 
that support a critical role for drebrin in regulating 
progranulin-dependent signaling and biological responses 
in bladder cancer.
RESULTS
Progranulin interacts with drebrin
In a search for novel progranulin interacting pro-
teins we performed pull-down assays with recombinant 
progranulin and protein extracts of 5637 bladder cancer 
cells. Samples were separated by SDS-PAGE, visualized 
with Coomassie blue staining and processed for mass 
spectrometry. Proteomic analysis of selected bands 
(Figure 1A, arrow) identified the neuronal F-actin-binding 
protein drebrin (developmentally regulated brain protein) [19, 
20] as a novel progranulin-interacting protein (Figure  1A, 
arrow). Next, we confirmed by immunoblotting that drebrin 
was expressed in various bladder cancer cells (Figure 1B) 
with a plasma membrane distribution in 5637 invasive 
urothelial cancer cells (arrows, Figure 1C). To further 
validate the interaction between progranulin and drebrin, 
we performed confocal microscopy analysis. We detected 
drebrin colocalization with progranulin in punctate vesicles 
(Figure 1D) suggesting that this interaction occurs upon 
progranulin internalization from cell membrane. The 
colocalization was further validated by line scanning confocal 
(bottom panel of Figure 1D), strongly supporting the notion 
that drebrin is a novel binding partner of progranulin.
Next, we confirmed the interaction between 
progranulin and endogenous drebrin by co-immuno-
precipitation assays in 5637 cells (Figure 2A). Drebrin 
was detectable in complex with endogenously expressed 
progranulin at low levels in unstimulated cells and 
this association decreased after 5 min of progranulin 
stimulation (Figure 2A, 5’). On the contrary, 30 min 
of progranulin stimulation strongly enhanced the 
progranulin/drebrin interaction (Figure 2A, 30’). 
Drebrin was not detectable when lysates of 5637 cells 
were immunoprecipitated with an unrelated antibody used 
as control (Figure 2A, IgG). These results were confirmed 
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by repeating coimmunoprecipation experiments in T24 
cells, where we detected the same kinetics of association 
between progranulin and endogenous drebrin (Figure 2B). 
Longer exposure of progranulin blots are included to 
show endogenous progranulin in total lysates (Figure 
2A and 2B). To confirm the results obtained by  anti-
progranulin antibodies, we performed reciprocal  co-IP 
and immunoprecipitated the complex using  anti-drebrin 
antibodies. We tried two commercially available anti-
bodies but both antibodies showed an extremely low 
ability to immunoprecipitate endogenous drebrin, thus 
preventing us in detecting progranulin in complex with 
drebrin. (Not shown)
Collectively, these results indicate that drebrin 
complexes with progranulin and may play a role in 
regulating progranulin-induced biological responses in 
bladder cancer cells.
Drebrin regulates progranulin-induced 
biological responses in urothelial cancer cells
We have previously established the critical role of 
progranulin in promoting motility of bladder cancer cells 
[10, 11]. Thus, as an initial step to determine drebrin 
function in progranulin-mediated responses in urothelial 
cancer cells, we transiently depleted endogenous drebrin 
Figure 1: Progranulin interacts with the F-acting-binding protein drebrin. (A) Proteomic identification of drebrin from 5637 
cell extract pulled-down with recombinant His-tagged progranulin. Samples were separated by SDS-PAGE, visualized with Coomassie 
blue staining and processed for mass spectrometry. Bands isolated from gel and analyzed are identified by the arrow. Drebrin identity was 
confirmed on a local Mascot server against the Swissprot database. (B) Drebrin immunodetection from lysates of various urothelial-carcinoma 
cell lines (Upper panel). B-actin was used as a loading control (lower panel). The blot is representative of two independent experiments. 
(C) Representative images of immunofluorescence analysis of drebrin expression in 5637 cells. Arrows show drebrin localization at the 
membrane. DAPI staining was used to label cell nuclei. (D) Drebrin colocalizes with progranulin after 5 min of stimulation as determined 
by confocal microscopy. Notice the distinct co-localization of drebrin and progranulin in the Z stacks (yellow staining, bottom right panel). 
The line-scanned profiles at the bottom of the fluorescence images show the distribution of the fluorescence signals of each channel between 
the white arrows in the corresponding confocal images. Pictures are representative of at least 10 independent fields from three independent 
experiments. An average of 300 cells was examined for each condition.
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Figure 2: Progranulin coprecipitates with drebrin in 5637 and T24 urothelial cancer cells. (A) Serum-starved (SFM) 5637 
and (B) T24 cells were stimulated with recombinant progranulin (80 nM) for 5 and 30 min (5’ and 30’). progranulin interaction with drebrin 
was assesses by coimmmunoprecipitation experiments. 3 mg of lysates from 5637 (A) and T24 (B) cells were immunoprecipitated with 
anti-progranulin polyclonal antibodies. Unrelated IgG (IgG) was used as control (A) Drebrin was detected by immunoblot using anti-
drebrin monoclonal antibodies. Blots are representative of two independent experiments.
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in 5637 and T24 cells by siRNA approaches and assessed 
cell migration. We achieved about ~90 and 75% depletion 
of endogenous drebrin in 5637 (Figure 3A) and T24 
(Figure 3B) cells, respectively as compared to cells treated 
with either vehicle or scrambled siRNA. Suppression of 
drebrin expression led to a robust inhibition of migration 
in both cell lines in response to progranulin stimulation 
(Figure 3A and 3B).
As drebrin is important for progranulin-evoked cell 
migration, we hypothesized that drebrin may also regulate 
the ability of urothelial cancer cells to invade through a 3D 
extracellular matrix upon progranulin stimulation. Thus, 
we used Matrigel-coated filters to examine invasive ability 
of 5637 cells depleted of endogenous drebrin (Figure 3C). 
Following exposure to progranulin (40 nM), there was a 
marked increase in the ability of vehicle- and control oligo-
transfected 5637 cells to invade a 3D matrix (Figure 3D) 
while drebrin knock-down significantly (**p < 0.01) reduced 
the invasive capacity of these cells (Figure 3D).
As progranulin-induced motility and invasion 
requires the activation of Akt and MAPK pathways 
[9–11], we sought to determine whether drebrin may 
regulate progranulin-dependent signaling and assessed by 
immunoblotting Akt and ERK1/2 activation in drebrin-
depleted 5637 cells (Figure 3E). Drebrin knockdown almost 
completely abolished progranulin-induced Akt activation, 
and caused > 50% reduction in ERK1/2 phosphorylation 
as compared to vehicle or siRNA control-transfected 5637 
cells (Figure 3E). The negative effect of drebrin depletion 
on progranulin signaling was reproducible in T24 cells but 
it more severely affected ERK1/2 activation as compared to 
Akt signaling (data not shown).
These results indicate that drebrin is a critical protein 
component for progranulin-mediated activation of Akt/
MAPK pathways leading to cell migration and invasion 
and may indeed function as an essential component of a 
progranulin signaling complex in bladder cancer cells.
Drebrin modulates progranulin-induced actin 
cytoskeleton remodeling
Cancer cell motility and invasion require a change 
in cellular morphology associated with actin remodeling 
[21, 22]. Because drebrin binds F-actin [19, 20], we 
investigated whether progranulin stimulation of 5637 
cells would affect the ability of drebrin to bind F-actin 
Figure 3: Drebrin modulates progranulin-induced motility and signaling of urothelial cancer cells. (A and B) 5637 and 
T24 cells were transiently transfected with vehicle, control oligos or On-Target siGenome pool of drebrin-specific oligos. 48 h post-
transfection cells were transferred to SFM or SFM supplemented with progranulin (40 nM) and counted for migration after 18 h. Data are 
the average of three independent experiments ±SD. *P < 0.05; **P < 0.01. Drebrin levels were assessed by immunoblotting with anti-
drebrin polyclonal antibodies. Densitometric analysis is expressed as arbitrary units. (C) Drebrin-depleted 5637 cells were assessed for 
invasive ability through Matrigel (D) as described in Materials and Methods. Data are the average of three independent experiments ±SD. 
**P < 0.01. (E) Activation of Akt and ERK1/2 in drebrin-depleted 5637 cells was determined by immunoblotting using phospho-specific 
antibodies. Densitometric analysis is expressed in arbitrary units. Blot is representative of three independent experiments.
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and mediate actin remodeling. To this end, we transiently 
transfected a GFP-tagged drebrin protein and assessed 
by immunofluorescence analysis the resultant F-actin 
network, visualized by rhodamine-phalloidin labeling. 
In serum-starved 5637 cells, full length GFP-drebrin 
(residue 1–707) staining was diffuse in the cytoplasm 
and colocalized with cortical F-actin (Figure 4A, 
arrows). Interestingly, progranulin stimulation induced 
redistribution of drebrin in F-actin-enriched spikes [23] 
at the membrane edge of 5637 cells (Figure 4A, arrows).
To further confirm the role of drebrin in regulating 
progranulin-induced F-actin remodeling, we depleted 5637 
cells of endogenous drebrin and analyzed F-actin network 
by rhodamine-phalloidin staining. Unstimulated siRNA 
control-transfected 5637 cells showed a well-organized 
F-actin network (arrows) and cortical actin (arrowhead) 
(Figure 4B, SFM), which was severely compromised 
after progranulin stimulation (Figure 4B, Progranulin). 
Significantly, drebrin-depleted 5637 cells showed no 
difference in F-actin remodeling between unstimulated 
and progranulin-stimulated 5637 cells (Figure 4C), 
which maintained the organized F-actin network (arrows) 
and intact cortical actin (arrow heads) after progranulin 
stimulation (Figure 4B).
Collectively, these results clearly suggest that 
drebrin regulates progranulin-induced cell motility of 
bladder cancer cells by modulating progranulin-mediated 
F-actin remodeling.
Drebrin modulates anchorage-independent 
growth and in vivo tumor formation
To ascertain drebrin activity in bladder cancer 
progression, we transfected a drebrin-specific 
shRNA-expressing plasmid in UMUC-3 urothelial 
carcinoma-derived cells. We choose these malignant 
cells as UMUC-3 cells form colonies in soft-agar and 
are tumorigenic in mice [24–27]. After selection in 
puromycin-containing media, we isolated two pools (mass 
cultures) of UMUC-3 cells where drebrin expression 
was abolished (Figure 5A, shDBN 4 and 6) as compared 
to either parental (P) or control-transfected (C) cells 
(Figure 5A). Notably, the drebrin-depleted UMUC-
3 (UMUC-3shDBN) cells showed a markedly-attenuated 
migratory ability in response to progranulin stimulation 
(***p < 0.001, Figure 5B). More importantly, UMUC-
3shDBN cells were significantly impaired in forming colonies 
in a soft-agar assay (***p < 0.001, Figure 5C), indicating 
that drebrin exerts an important role in regulating 
anchorage-independent growth of bladder cancer cells.
Based on this finding that drebrin regulates 
anchorage-independent growth of UMUC-3 bladder 
cancer cells, we generated mouse xenograft models and 
investigated whether targeting drebrin could suppress the 
ability of UMUC-3 cells to form tumors in vivo. UMUC-3 
shScr (UMUC-3shScr) control and UMUC-3shDBN cells were 
implanted subcutaneously into the left and right flanks 
respectively of 6 week-old Rag2–/– mice which lack in 
the ability to initiate V(D)J rearrangement, leading to a 
severe immunocompromised phenotype. Once tumors 
were established, tumor sizes were monitored until the 
largest tumor reached ~2000 mm3 in size. Importantly, 
All control UMUC-3shScr cells generated tumor xenografts 
in contrast to the debrin-depleted UMUC-3shDBN cells 
which generated tumors only in ~30%, and in addition, 
the average tumor volume was significantly smaller than 
control (***p < 0.001, Figure 6A and 6B). To confirm that 
the tumor xenografts had indeed reduced expression of 
drebrin, we performed immunofluorescence analysis on 
frozen sections of tumors after the animals were sacrificed. 
Indeed, we found that drebrin levels were significantly 
depleted in the UMUC-3shDBN xenografts (Figure 6C). On 
the contrary, drebrin depletion did not affect progranulin 
levels, which were very similar in control and drebrin-
depleted UMUC-3 cells (Figure 6D).
Collectively, these findings provide a strong 
evidence for a role for drebrin in regulating tumor 
formation in vivo and suggest a drebrin mechanism 
of action which is independent of a possible effect 
on progranulin levels. Because we have preliminary 
evidences that progranulin depletion affects as well tumor 
formation in vivo, these results additionally support 
the hypothesis that drebrin functions by regulating 
downstream progranulin signaling.
Drebrin expression is upregulated in bladder 
cancer tissues
Next, we assessed whether drebrin expression 
is altered in human bladder cancer. To this end, we 
utilized a human bladder tumor microarray containing 45 
validated cases in duplicate of various types of bladder 
cancers and normal bladder tissue (AccuMax™ array). 
In normal bladder tissue, drebrin was only detectable 
primarily in the submucosal mesenchyme (arrows, 
Figure 7A). Higher magnification view showed that 
drebrin was primarily expressed by vascular smooth 
muscle cells (arrows, Figure 7B) and nerves (arrowheads, 
Figure 7B). Notably, in all malignant tissues examined 
there was a marked upregulation of drebrin. Drebrin 
was markedly elevated in the epithelial components of 
both highly and poorly differentiated urothelial cancer 
(Figures 7C–7H). In addition, the angiogenic component 
of various bladder cancers, evident in the high grade 
transitional cell carcinomas (arrows, Figures 7F and 7G), 
showed enhanced expression of drebrin, suggesting that 
it might be also involved in positively regulating tumor 
angiogenesis. Significantly, the staining intensity index on 
drebrin expression levels of urothelial carcinoma tissues 
demonstrated that drebrin expression in high grade T2, 
T3 and T4 tumors is significantly increased over lower 
grade (Ta, T1) (**p < 0.01) and normal bladder tissues 
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Figure 4: Drebrin is critical for progranulin-mediated F-actin remodeling. (A) GFP-tagged wild type drebrin construct has 
been previously described [23]. (ADF-H) actin-depolymerizing factor homology domain. AB: actin binding domain. AE: adult specific 
exon. 5637 cells were transiently transfected with the GFP-tagged drebrin construct, serum-starved for 24 h and then stimulated with 
progranulin (40 nM) for 30 min. F-actin structures were assesses by immunofluorescence analysis as described in Material and Methods 
using Rhodamine-phalloidin. Pictures are representative of at least 10 independent fields from three independent experiments. An average 
of 300 cells was examined for each condition. Arrows indicate various F-actin structures. 5637 cells were transiently transfected with 
control oligos (B) or On-Target siGenome pool of drebrin-specific oligos (Dharmacon) (C) serum-starved for 24 h and stimulated with 
progranulin (40 nM) for 30 min. Immunofluorescence analysis was performed as described in Material and Methods. F-actin was detected 
using anti-phalloidin staining. Drebrin levels were analyzed using anti-drebrin monoclonal antibodies. Pictures are representative of at 
least 10 independent fields from three independent experiments. An average of 300 cells was examined for each condition. Arrows indicate 
F-actin networks while arrowheads identify cortical actin.
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Figure 5: Stable depletion of endogenous drebrin in tumorigenic UMUC-3 urothelial cancer cells inhibits motility and 
anchorage-independent growth. (A) The generation of UMUC-3/pRS-control and UMUC-3/pRS-shDBN cells has been described 
in Materials and Methods. Drebrin expression in lysates from parental (P), control- (C) or shRNA drebrin-transfected (shDBN) UMUC-3 
cells was detected by immunoblot. (B) Migration of the various UMUC-3 cell lines was performed using transwells as described in detail in 
Materials and Methods. The experiment is the average of three independent experiments run in duplicates ±SD. **P < 0.01. ***P < 0.001. 
(C) Anchorage-independent growth was measured by colony formation in soft-agar as previously described [10]. Colonies > 150 μM were 
counted. The experiment is the average of three independent experiments run in duplicates ±SD. ***P < 0.001.
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Figure 6: Drebrin regulates tumor formation in vivo. (A) Tumor growth plot of mice (n = 18) injected with UMUC-3/sh-control 
(shCon) and UMUC-3/sh-drebrin (shDBN) cells at day 52. ***P < 0.001. (B) Representative macroscopic photographs of UMUC-3 control 
(shCon) and drebrin-depleted (shDBN) tumors at day 52. (C and D) Tumors extracted from UMUC-3/sh-control (shCon) and UMUC-3/ 
sh-drebrin-injected (shDBN) mice were analyzed for drebrin (C) and progranulin (D) expression by immunofluorescence analysis. 
Three-dimensional surface plots are indicative of drebrin (C) and progranulin (D) expression levels in the relative fluorescence images. 
Accompanying scale bars on the right depict signal intensity.
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(***p < 0.001) (Figure 7I). In addition progranulin 
and drebrin expression partially colocalized in high 
grade urothelial carcinoma tissues, as demonstrated by 
immunofluorescence analysis on a frozen high grade 
urothelial carcinoma tissue (Figure 7J–7L).
DISCUSSION
We have discovered a novel interaction between 
the growth factor progranulin and the F-actin-binding 
protein drebrin and provide several lines of evidence that 
underscore a key role for drebrin in regulating progranulin 
bioactivity in bladder cancer. First, we show that drebrin is 
expressed in urothelial carcinoma-derived cell lines where 
it associates with progranulin as demonstrated by pull-
down experiments, proteomic approaches, coimmuno-
precipitation assays and colocalization experiments using 
confocal laser microscopy. Second, we show for the first 
time that drebrin is required for progranulin-induced 
motility, invasion and activation of the Akt/MAPK 
pathways in two malignant urothelial cells. Third, we 
provide robust evidence that drebrin regulates progranulin-
dependent F-actin remodeling and that this bioactivity 
also requires drebrin expression. Fourth, we show that 
tumorigenic UMUC-3 cells stably depleted in drebrin form 
fewer and smaller tumors in immunocompromised animals 
than the corresponding wild-type cells. Finally, we show 
that drebrin expression in upregulated in several human 
bladders cancers. Both highly and poorly differentiated 
bladder cancers express high levels of drebrin in the tumor 
proper. Notably, drebrin expression in high grade T2, T3 
and T4 tumors is significantly increased over lower grade 
(Ta, T1) and normal bladder tissues.
Debrin was originally identified in the brain 
of chick embryos [20, 28] and it is expressed in two 
isoforms: an embryonic type (drebrin E) and an adult type 
(drebrin A), whose sequence is almost identical except 
for an internal insert sequence in drebrin A, but no clear 
functional differences have be so far described [20]. Most 
of the past work on drebrin expression and activity has 
been focused on neurons, in which drebrin binds F-actin 
and controls actin filament dynamics, neurite morphology 
and outgrowth [23, 29]. By affecting actin remodeling, 
drebrin plays a significant role in regulating cell motility 
in the physiology [30–32] and pathology of neuronal cells 
[33]. Drebrin expression has been more recently detected 
in non-neuronal tissues and cells, including stomach and 
kidney epithelia [34] and T cells, where drebrin binds 
the chemokine receptor CXCR4 and regulates immune 
synapsis [35].
Figure 7: Drebrin is upregulated in bladder cancer tissues. (A–H), Panels of light micrographs depicting the distribution of 
immunoreactive drebrin in normal bladder (A and B) and various types of urinary cancers as indicated (C–H) Notice that in normal 
bladder, drebrin is essentially not expressed in the mucosa (Mu, a) but is expressed in the submucosal blood vessels and nerves (arrows 
and arrowheads, respectively, panel B). Drebrin is expressed at high levels in the epithelial components of all cancers (Ca) studied and 
often in the tumor vasculature (arrows in panels f and g). Bars = 100 μm. (I) Quantification of the drebrin staining was done using ImageJ 
software. Various images of normal (n = 9); Ta, T1 (n = 10) and T2, T3, T4 (n = 13) urothelial carcinoma tissues were analyzed. Briefly, the 
threshold of each image was adjusted in order to show only the specific staining. The representative areas of staining were then quantified 
and plot using SigmaPlot. (L–J) Drebrin and progranulin expression in frozen high grade urothelial carcinoma tissues was analyzed 
by immunofluorescence analysis. Arrows (L) indicate some areas of colocalization. Three-dimensional surface plots are indicative of 
progranulin (M) and drebrin (N) expression levels in the relative fluorescence images.
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Our current findings provide the first evidence of 
drebrin expression and interaction with the growth factor 
progranulin in urothelial-carcinoma derived cells where 
drebrin exerts an essential role in modulating progranulin-
induced biological responses.
The progranulin-interactive drebrin fragment we 
isolated by mass spectrometry is conserved between drebrin 
A and E isoforms, and the anti-drebrin antibodies used in 
these studies do not discriminate between the different 
drebrin isoforms. However, because drebrin A is considered 
the neuron-specific isoform, while drebrin E expression 
is more ubiquitous [36], we can reasonably assume that 
bladder cancer cell lines likely express drebrin E. We have 
transiently expressed both drebrin isoforms in 5637 cells 
and we could not detect any differences in their ability to 
regulate progranulin-dependent F-actin remodeling.
Our previous work has established an essential role 
for progranulin in modulating migration and invasion 
of bladder cancer cells. Progranulin acts as an autocrine 
growth factor and regulates motility in part by activating 
paxillin and promoting paxillin colocalization with FAK 
at dynamic focal adhesion sites at the leading edge of 
migrating cells [10, 11]. Notably, progranulin stimulation 
of 5637 urothelial cancer cells does not significantly 
enhance cell proliferation [9] indicating that the ability of 
progranulin to promote cell motility is dissociated from a 
potential effect on cell growth.
Progranulin stimulation of 5637 cells induces drebrin 
redistribution at previously described F-actin spikes [23], 
which are morphologically very similar to dynamic adhesions 
at the membrane edge of motile 5637 cells [10, 11]. Thus, 
we propose that drebrin, by regulating F-actin remodeling, 
would modulate progranulin-dependent focal adhesion 
turnover of migrating bladder cancer cells. However, whether 
drebrin functionally interacts with paxillin and/or FAK at 
focal adhesions remains to be established. Significantly, 
recent experiments from our laboratories have demonstrated 
that the FAK homolog Proline-Rich Tyrosine Kinase 2 
(Pyk2) is upregulated in bladder cancer tissues compared 
to normal tissue controls and plays a more important role 
than FAK in regulating IGF-I-induced motility and invasion 
of urothelial carcinoma cells [37]. We have preliminary 
evidence supporting a role of Pyk2 in progranulin-dependent 
signaling of urothelial cancer cells; however, it remains to 
be established whether Pyk2 would interact with drebrin 
and contribute with drebrin to the regulation of F-actin 
remodeling and/or focal adhesion turnover.
A limitation of our studies is that, although we 
have demonstrated by several independent approaches 
that progranulin interacts with drebrin, we cannot 
totally exclude the possibility that this interaction may 
not be direct but mediated through the formation of a 
multiprotein complex, which may regulate early events of 
progranulin signaling. As drebrin is not a trans-membrane 
protein, the interaction with progranulin is likely 
occurring at early stages of progranulin internalization 
from the cell membrane. However, the mechanisms 
regulating progranulin uptake and endocytosis are very 
poorly characterized, especially in bladder cancer cells. 
As we mentioned in the Introduction, in neuronal cells 
progranulin interacts with sortilin, which promotes 
progranulin internalization and targeting for lysosomal 
degradation [14]. We have discovered that sortilin is 
expressed in urothelial cancer cell lines suggesting that 
sortilin might complex with progranulin and drebrin in 
early endocytic compartments and may play any role in 
modulating early events of progranulin signaling.
Our studies point out to a very important role 
for drebrin in regulating bladder cancer initiation and 
progression. Drebrin is essential for progranulin-induced 
signaling of urothelial cancer cells as in fact drebrin 
depletion significantly inhibits the activation of both 
the Akt and MAPK pathways, which are essential for 
progranulin-dependent motility and invasion of urothelial 
cancer cells [10, 11]. More importantly, drebrin depletion 
profoundly affects the ability of urothelial cancer cells 
to grow in anchorage-independency and form tumors in 
xenograft models suggesting the possibility that drebrin 
may not only affect progranulin-dependent responses but 
also regulate additional pathways, which may converge 
with progranulin signaling thereby promoting bladder 
tumor initiation and possibly progression.
There is a great interest at the moment in the 
identification of novel biomarkers for prognosis and 
treatment selection of advanced bladder cancers [38–40]. 
Our results demonstrated drebrin overexpression in 
various bladder cancer tissues and drebrin levels are 
enhanced in high grade urothelial carcinoma compared 
to lower grade and normal urothelial tissue controls. In 
addition drebrin partially colocalized with progranulin 
in high grade urothelial carcinoma tissues. These results 
suggest that drebrin expression in bladder cancer tissue 
may work in conjunction with progranulin levels as a 
novel biomarker for bladder cancer and may identify 
tumors likely to progress to the invasive phenotype. 
However, additional studies including the analysis of 
metastatic bladder cancer tissue samples are required to 
clearly establish a role for drebrin in tumor progression.
In summary, our studies have identified the F-actin 
protein drebrin as a novel progranulin interacting protein 
critical for motility, invasion, anchorage-independent 
growth and tumor formation in vivo of urothelial cancer 
cells. Drebrin may constitute therefore a novel target for 
therapeutic intervention in bladder tumors.
MATERIALS AND METHODS
Cell lines
Urothelial carcinoma-derived human 5637, T24 and 
UMUC-3 cells were obtained by ATCC (Manassas, VA, 
USA). 
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5637 and T24 cells were maintained in RPMI 
medium with 10% fetal bovine serum (FBS). UMUC-
3 cells were maintained in MEM with EARL medium 
with 10% FBS. Serum-free medium (SFM) is DMEM 
supplemented with 0.1% bovine serum albumin and 50 
μg/ml of transferrin (Sigma-Aldrich, St Louis, MO, USA).
Pull-down assays with recombinant progranulin 
and proteomic analysis
Serum-starved 5637 cells were stimulated with 
progranulin (40 nM) for 5 min and lysates collected in 
NP-40 lysis buffer containing Protease and Phosphatase 
Inhibitor Cocktail (Thermo Scientifics, Waltham, MA 
USA). After preclearing for 1 h with Ni-NTA-agarose 
beads (QIAGEN, Valencia, CA, USA), lysates (10 mg) 
were first incubated with or without 7 μg of recombinant 
HIS-tagged progranulin overnight a 4oC and then with 
Ni-NTA-agarose beads for 1 h. Beads were washed with 
lysis buffer and resuspended in Laemmli buffer. Samples 
were separated by SDS-PAGE, visualized with Coomassie 
blue staining and processed for mass spectrometry at the 
Proteomic Core Facility of the Kimmel Cancer Center. 
Bands were excised and digested with trypsin after 
reduction and alkylation. Peptides were separated on a 
10-cm C18 column and analyzed on a Thermo LCQ 3D ion 
trap using the nano-source. MS/MS spectra were searched 
on a local Mascot server against the Swissprot database. All 
peptides were identified with a confidence of at least 95%.
Confocal microscopy
5637 cells on slides were serum-starved overnight 
and treated with progranulin (40 nM) for 5 min. Cells were 
then washed with PBS and fixed with 4% PFA for 30 min 
at room temperature. Subsequently, slides were subjected 
to immunofluorescence and confocal analysis as previously 
described [9, 10, 37, 41–43]. Primary antibodies were anti-
progranulin polyclonal (USBiologicals, Swampscott, MA, 
USA) and anti-drebrin monoclonal antibodies (Abcam, 
Cambridge, MA, USA). Secondary antibodies were goat 
anti-mouse IgG Alexa Fluor® 488 and goat anti-rabbit IgG 
Alexa Fluor® 594 antibodies (Invitrogen, Grand Island, NY, 
USA). Confocal analysis was carried out using a 63x, 1.3 
oil-immersion objective of a Zeiss LSM-78 confocal laser-
scanning microscope. To determine colocalization of the 
two proteins, Z-stack series were acquired maintaining the 
same slice interval. All images were analyzed using ImageJ 
and Adobe Photoshop CS6 (Adobe Systems). Line scanning 
plots were performed utilizing SigmaPlot software.
Co-immunoprecipitation and immunoblotting
Serum-starved 5637 and T24 cells were stimulated 
for 5 and 30 min with 80 nM progranulin and lysates (3 
mg) immunoprecipitated with anti-progranulin polyclonal 
antibodies (USBiologicals). Progranulin was detected by 
immunoblot using anti-progranulin polyclonal antibodies 
(USBiologicals) while drebrin expression was detected 
using either anti-drebrin polyclonal antibodies (Sigma-
Aldrich) or anti-drebrin monoclonal antibodies (Abcam).
Drebrin depletion by siRNA approaches
Transient depletion of endogenous drebrin in 5637 
and T24 cells was achieved by siRNA approaches using 
vehicle, control oligos or On-Target siGenome pool of 
drebrin-specific oligos (Dharmacon, Lafayette, CO, USA). 
Cells were transfected with 400 pM of oligos using the 
TransIT-TKO® Transfection Reagent (Mirus, Madison, 
WI, USA). Biological responses and drebrin expression 
levels were assessed after 72 h post-transfection.
Migration, wound healing and invasion assays
HTS FluoroBloks™ inserts (Becton Dickinson, 
Durham, NC, USA) were saturated with PBS-1% bovine 
serum albumin for 2 h at room temperature. Serum-
starved cells were labeled with DiI (Molecular Probes, 
Grand Island, NY, USA) for 20 min at 37°C and seeded 
in the HTS FluoroBloks™ upper chamber in SFM 
or SFM supplemented with progranulin (40 nM) and 
incubated at 37°C for 18 h. Membranes were fixed in 4% 
paraformaldehyde, mounted on slides and migrated cells 
were counted and photographed with a Zeiss Axiovert 
200 M cell live microscope. Cell invasion was assessed 
by using BD Matrigel™ Invasion Chambers (BD Biocoat, 
Bedford, MA, USA) with 8.0 μm filter membranes. Cells 
(5x104) in 200 μl of SFM were plated onto each filter, and 
750 μl of SFM or SFM supplemented with progranulin (40 
nM) in the lower chamber. After 24 h filters were washed, 
fixed, and stained with Coomassie Brilliant Blue. Cells on 
the upper surface of the filters were removed with cotton 
swabs. Cells that had invaded to the lower surface of the 
filter were counted under the microscope.
Immunoblot detection of activated signaling 
pathways
Serum-starved cells were then stimulated with 
progranulin (40 nM) for 10 min. The activation of Akt 
and ERK1/2 was analyzed by western immunoblot using 
phospho-specific antibodies (Cell Signaling Technology, 
Beverly, MA, USA) as described [44]. Total levels of Akt 
and ERKs were monitored with anti-Akt and anti-ERK1/2 
antibodies (Cell Signaling Technology).
Drebrin expression and F-actin remodeling
The GFP-drebrin fusion proteins GFP-drebrin A wt 
was previously described [23]. 5637 cells were transfected 
on slides using the TransIT®-Prostate Transfection Kit 
(Mirus). 48 h after transfection, cells were serum-starved 
for 24 h and then treated with either 1X PBS or 40 nM 
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of progranulin for 30 min. Cells were fixed for 30 min 
at room temperature with 4% paraformaldehyde in 1X 
PBS and permeabilized for 30 seconds with 0.01% 
Tween in 1X PBS. F-actin staining was assessed by 
Rhodamine-phalloidin (Invitrogen) for 20 min and then 
fixed with Vectashield (Vector, Burlingame, CA, USA). 
Drebrin expression was detected using an anti-drebrin 
polyclonal antibody (Sigma-Aldrich) followed by a goat 
anti-rabbit IgG Alexa-Fluor 594 secondary antibody. 
Immunofluorescence analysis was performed using a 
LEICA DM5500B fluorescent microscope.
Generation of progranulin-depleted UMUC-3 
cells
UMUC-3 cells stably depleted of endogenous 
drebrin were generated by transfecting the pRS vector, 
the pRS-shRNA-control (scrambled shRNA) and pRS/
shDBN plasmids (OriGene Technologies, Inc., Rockville, 
MD, USA) using the TransIT®-Prostate Transfection Kit 
(Mirus). Cells were selected in medium supplemented 
with 2 μg/ml of Puromycin. After selection, pools of 
drebrin-depleted UMUC-3 cells were tested for drebrin 
expression levels by immunoblot using anti-drebrin 
monoclonal antibodies (Abcam).
Colony formation assay in soft-agar
Colony formation in soft-agar was performed as 
previously described [10]. Cells were counted after four 
weeks in culture. Colonies > 150 μm were scored as positive.
Tumor xenografts
Experiments using 7- to 10-week-old Rag2–/– 
mice were carried out according to protocols approved 
by the Institutional Review Board of Thomas Jefferson 
University. 4 × 106 UMUC-3/sh-control and sh-drebrin 
cells were injected subcutaneously in two distinct sites 
of mice flanks (control cells in the upper-left flank and 
drebrin-depleted cells in the lower-right flank). Three 
independent experiments with 6 mice each were performed 
(n = 18). Once tumors were established, tumor growth was 
measured every 2 days with a micro-caliper utilizing the 
following formula: V = a(b2/2), where a and b represent 
the larger and small diameters, respectively. When tumors 
reached 2000 mm3 in size, mice were sacrificed and tumors 
surgically dissected and divided. One half was snap frozen 
in liquid nitrogen for further biochemical analysis, whereas 
the other half was embedded in OCT medium (Sakura 
Finetek, Torrance, CA, USA) and frozen at –20°C. 10 μm 
thick cryostat sections were cut from the blocks, mounted 
on slides and subjected to immunofluorescence analysis 
utilizing a mouse monoclonal anti-drebrin antibody (Santa 
Cruz, Dallas, Texas, USA).
Colocalization of progranulin and drebrin was 
assessed by immunofluorescence analysis on an unidentified 
high grade human bladder tissue using anti-drebrin and 
progranulin antibodies described above. Three-dimensional 
surface plots were created with ImageJ and represent 
drebrin and/or progranulin expression based on the intensity 
of the immunofluorescence signal.
Immunohistochemical detection of drebrin in 
bladder cancer tissues
Drebrin expression was analyzed by immuno-
histochemistry on an AccuMax™ bladder cancer tissue 
microarray (Petagen Inc., Seodaemun-gu, Seoul, Korea) 
at the Translational Core Facility of the Kimmel Cancer 
Center. The anti-drebrin monoclonal antibody was used 
at a 1:200 dilution. Detailed specifications of the bladder 
tissue array can be found at: tissuearray.petagen.com/
main/products.php?no=110.
Quantification of the drebrin staining in urothelial 
carcinoma tissues was done using ImageJ software. Various 
images of normal (n = 9); Ta, T1 (n = 10) and T2, T3, T4 
(n = 13) urothelial carcinoma tissues were analyzed. Briefly, 
the threshold of each image was adjusted in order to show 
only the specific staining. The representative areas of 
staining were then quantified and plot using SigmaPlot.
Statistical analysis
Results of multiple experiments are expressed as 
mean ± SD. All statistical analyses were carried out with 
SigmaStat for Windows version 3.10 (Systat Software, 
Inc., Port Richmond, CA). Results were compared using 
the two-sided Student’s t test. Differences were considered 
statistically significant at p < 0.05.
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